AI Insight
A study in Kalamazoo, Michigan found that emergency department visits for cannabinoid hyperemesis syndrome (CHS)—a condition causing severe cyclic vomiting in cannabis users—increased 57.2-fold after recreational cannabis legalization in December 2018, rising from 6 cases in the prior nine years to 274 cases in seven post-legalization years. An environmental scan revealed that only one of the licensed cannabis retailers mentioned CHS as a warning, with no symptom descriptions or medical guidance, and neither state nor local health department websites provided CHS information. The researchers recommend mandating CHS-specific warnings in point-of-sale materials to address this educational gap.
Why it matters
CHS is frequently misdiagnosed, leading to repeated emergency visits and high diagnostic costs, yet consumers receive minimal information about this risk when purchasing legal cannabis. Better consumer education could reduce the healthcare burden and help users make more informed decisions about cannabis consumption.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: Since Michigan’s legalization of recreational adult-use cannabis in December 2018, health care providers in the city of Kalamazoo, Michigan, have informally observed an increase in cannabinoid hyperemesis syndrome (CHS) presentations, although the extent of this increase has not been formally characterized locally. CHS is frequently underrecognized and misdiagnosed, often resulting in repeated emergency department (ED) visits and substantial diagnostic costs before a diagnosis is reached. Despite this clinical and financial burden, it is unclear whether consumers are adequately informed of this risk through point-of-sale or public health resources. Methods: A cross-sectional environmental scan was conducted to identify publicly available educational content about CHS on the websites of licensed cannabis retailers in Kalamazoo and relevant public health agencies. Provisioning centers and public health websites were screened using a structured coding rubric developed specifically for the environmental scan to assess the presence, depth, web page placement, and intended audience of CHS-related content. Additionally, the electronic medical records at a local teaching hospital in Kalamazoo were queried to identify ED visits with a primary diagnosis of CHS from January 1, 2010 to December 31, 2025. Results: Before the legalization of marijuana, the hospital recorded six ED encounters with the primary diagnosis of CHS between January 2010 and November 2018, and 274 ED encounters between December 2018 and December 2025 (mean age: 29 years; 157 females, 123 males). The incidence rate of CHS-related ED encounters was 57.2 times higher during the post-legalization period than during the pre-legalization period (95% CI, 26.0-157.3; exact Poisson rate-ratio test, p < 0.0001). Among the licensed Kalamazoo provisioning centers reviewed, only one mentioned CHS as a warning but did not describe symptoms or offer medical guidance. CHS content was not identified on the websites of the state or local health departments. Conclusion: Despite the growing clinical concern regarding CHS, consumer-facing educational resources remain scarce. Although this study cannot establish a causal relationship between the availability of CHS-related educational content and the observed increase in ED encounters following legalization, it identifies a substantial lack of CHS-specific warnings in the evaluated consumer-facing resources. Given the clinical and potential economic burden associated with delayed CHS recognition, we recommend that Michigans existing point-of-sale pamphlet requirement be amended to include CHS-specific warning language.